Skip to main content

Peer-review policy

Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.

Allergy, Asthma & Clinical Immunology operates using a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.

Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication.  Following recommendation from the Handling Editor, final decisions rest with the Editor-in-Chief who aims to provide an initial decision within six weeks. In cases where authors challenge an Editor's negative decision with well founded arguments, the Editors may consult with members of the Editorial Board or send the manuscript to be sent to one or two additional reviewers.

Manuscripts are sent to statisticians at the request of reviewers.

The official journal of CSACI

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.6
    5-year Journal Impact Factor: 3.5
    Source Normalized Impact per Paper (SNIP): 0.904
    SCImago Journal Rank (SJR): 0.749

    Speed 2023
    Submission to first editorial decision (median days): 18
    Submission to acceptance (median days): 140

    Usage 2023
    Downloads: 1,545,686
    Altmetric mentions: 2,123